MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix: RICs (Regional Innovation Clusters), Consortia, Multi-Disciplinary Centers
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Bioscience Regional Clusters & HotSpots
*Industry: Northern California & Silicon Valley
Arcus Biosciences, Inc. (NYSE: RCUS)
Organization & Developments: Arcus
Parents
Arcus Biosciences, Inc. (NYSE: RCUS)
Children
*Arcus Biosciences
2021: Arcus Biosciences: Highly Valued Even Without A Phase 3 Study
2022: Arcus has partnered with the Gilead Company (NASDAQ: GILD) to develop three investigational molecules: domvanalimab, an Fc-silent anti-TIGIT antibody, etrumadenant, a dual adenosine A2a/A2b receptor antagonist, and zimberelimab, an anti-PD1 antibody.
2023: Arcus Biosciences: Showing There Might Be Something To TIGIT After All_ seekingalpha.com
2023: Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey_ seekingalpha.com
2024: Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
2024: Arcus Biosciences obtains loan facility with Hercules Capital worth $250m
2024: Arcus Biosciences: Advancing On Several Fronts
2024: Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)
2024: Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
2024: Arcus' new HIF-2a data in kidney cancer hint at potential edge over Merck's Welireg, analysts say
2024:Stocks Flashing Renewed Technical Strength: Arcus Biosciences
2025: Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025
2025: Arcus: Excellent Pipeline And Collaborations, Cash Runway_ seekingalpha.com
Jumps
Finance & Acquisitions: Arcus
Key People: Arcus